Recent animal study shows branded hyaluronic acid Mobilee may improve biomarkers of osteoarthritis
Results showed, that compared to baseline, subjects taking the HA supplement saw significant increases in HA concentration in the synovial fluid and a decrease in PON-1 concentration.
Photo © iStockphoto.com/Wavebreakmedia
Bioiberica (Barcelona, Spain) has announced to results of a randomized, double blind clinical study evaluating the effects of orally administered hyaluronic acid – in the form of the company’s branded ingredient Mobilee – on synovial fluid concentrations of several selected biomarkers in 55 dogs. In the study, published in the journal Animals1, 30 dogs were given the hyaluronic acid (HA) supplement and 25 dogs were given a placebo daily for 10 weeks after surgery.
The key biomarkers of osteoarthritis researchers measured were: HA, haptoglobin, nitric oxide, and paraoxonase-1 (PON-1). Results showed, that compared to baseline, subjects taking the HA supplement saw significant increases in HA concentration in the synovial fluid and a decrease in PON-1 concentration.
“Despite this research involving dogs specifically, the results are an important indicator for Mobilee’s effect in humans too. The findings further contribute to a robust body of evidence which indicates Mobilee’s ability to increase endogenous HA levels and its role in supporting joint and muscle health,” said Jaume Reguant, healthcare director for Bioiberica, in a press release. “Science is at the heart of everything we do at Bioiberica – it’s the means through which we continue to deliver cutting-edge ingredients to support our customers’ product developments.”
Reference
- Aguanda CIS et al. “Effects of oral hyaluronic acid administration in dogs following tibial tuberosity advancement surgery for cranial cruciate ligament injury.” Animals, vol. 11, no. 5 (2021): 1264
